Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Nov 14 2019 Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
- Nov 12 2019 Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
- Sep 18 2019 Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
- Sep 17 2019 Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
- Sep 3 2019 Oramed to Present at Three Upcoming Conferences